

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandra, Virginia 22313-1450 www.unpto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/556,452	11/10/2005	Alexis S.R. Ashley	GB 030074	3785
24737 7590 02/04/2009 PHILIPS INTELLECTUAL PROPERTY & STANDARDS			EXAMINER	
P.O. BOX 3001		HICKS, CHARLES N		
BRIARCLIFF	MANOR, NY 10510		ART UNIT PAPER NUMBER	
			2424	
			MAIL DATE	DELIVERY MODE
			02/04/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

A	Application No.	Applicant(s)
Notice of Abandonment	10/556,452	ASHLEY ET AL.
Notice of Abandonment E	Examiner	Art Unit
с	CHARLES N. HICKS	2424

	CHARLES N. HICKS 2424	
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address	
This	application is abandoned in view of:	
(a)	Applicant's failure to timely file a proper reply to the Office letter mailed on <u>15 April 2008</u> . ☐ A reply was received on(with a Certificate of Mailing or Transmission dated), which is after the expiration o period for reply (including a total extension of time of month(s)) which expired on	
(b)) 🗌 A proposed reply was received on, but it does not constitute a proper reply under 37 CFR 1.113 (a) to the final reje	ction
	(A proper reply under 37 CFR 1.113 to a final rejection consists only of: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114).	
(c)) A reply was received on but it does not constitute a proper reply, or a bona fide attempt at a proper reply, to the not final rejection. See 37 CFR 1.85(a) and 1.111. (See explanation in box 7 below).	n-
(d)	☑ No reply has been received.	
	Applicant's failure to timely pay the required issue fee and publication fee, if applicable, within the statutory period of three more from the mailing date of the Notice of Allowance (PTOL-85).	
(a)	D The issue fee and publication fee, if applicable, was received on (with a Certificate of Mailing or Transmission), which is after the expiration of the statutory period for payment of the issue fee (and publication fee) set in the No Allowance (PTOL-65).	
(b)	The submitted fee of \$ is insufficient. A balance of \$ is due.	
	The issue fee required by 37 CFR 1.18 is \$ The publication fee, if required by 37 CFR 1.18(d), is \$	
(c)	The issue fee and publication fee, if applicable, has not been received.	
3. 🔲 .	Applicant's failure to timely file corrected drawings as required by, and within the three-month period set in, the Notice of Allowability (PTO-37).	
(a)	Proposed corrected drawings were received on (with a Certificate of Mailing or Transmission dated), which i after the expiration of the period for reply.	S
(b)	□ No corrected drawings have been received.	
	The letter of express abandonment which is signed by the attorney or agent of record, the assignee of the entire interest, or a the applicants.	ll of
	The letter of express abandonment which is signed by an attorney or agent (acting in a representative capacity under 37 CFF 1.34(a)) upon the filing of a continuing application.	ł
	The decision by the Board of Patent Appeals and Interference rendered on and because the period for seeking court re of the decision has expired and there are no allowed claims.	eview
7. 🛛	The reason(s) below:	
	Attorney for applicant was contacted regarding the impending abandonment of the application due to a lack of tin response.	nely
	ris Kelley/ ervisory Patent Examiner, Art Unit 2424	
Petitin	ons to revive under 37 CER 1.137(a) or (b) or requests to withdraw the holding of abandonment under 37 CER 1.181, should be promptly filed	d to

reautions to revive under 37 CFR 1.137(a) or (t minimize any negative effects on patent term. U.S. Patent and Trademark Office PTOL-1432 (Rev. 04-01)